Who are Timolol + LCP's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ISOPROTERENOL, Norepinephrine Bitartrate In 5% Dextrose, Beta blocker, aspirin, clopidogrel, Intravenous amiodarone(1), intralesional propranolol injection, Istalol and Optive.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/timolol-lcp.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Timolol + LCP — Competitive Intelligence Brief

Timolol + LCP (Timolol + LCP) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-blocker. Area: Cardiovascular.

phase 3 Beta-blocker Beta-adrenergic receptors Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Timolol + LCP (Timolol + LCP) — Centre Hospitalier Universitaire de Nice. Timolol is a non-selective beta-adrenergic receptor blocker, and LCP is a beta-blocker.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Timolol + LCP TARGET	Timolol + LCP	Centre Hospitalier Universitaire de Nice	phase 3	Beta-blocker	Beta-adrenergic receptors
ISOPROTERENOL	ISOPROTERENOL		marketed	Beta-adrenergic agonist	beta-adrenergic receptors	1956-01-01
Norepinephrine Bitartrate In 5% Dextrose	NOREPINEPHRINE	Pfizer	marketed	Catecholamine	alpha-adrenergic receptors, beta-adrenergic receptors	1950-01-01
Beta blocker, aspirin, clopidogrel	Beta blocker, aspirin, clopidogrel	Spanish Society of Cardiology	marketed	Combination antithrombotic and antihypertensive therapy	Beta-adrenergic receptors; COX-1; P2Y12 receptor
Intravenous amiodarone(1)	Intravenous amiodarone(1)	Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud	marketed	Class III antiarrhythmic agent	Potassium channels, sodium channels, calcium channels, beta-adrenergic receptors
intralesional propranolol injection	intralesional propranolol injection	Ain Shams University	marketed	Beta-adrenergic antagonist	Beta-adrenergic receptors (non-selective)
Istalol and Optive	Istalol and Optive	Bp Consulting, Inc	marketed	Beta-blocker (Istalol); Artificial tear/lubricant (Optive)	Beta-adrenergic receptors (Istalol); Non-specific ocular surface lubricant (Optive)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-blocker class)

Abbott · 1 drug in this class
Centre Hospitalier Universitaire de Nice · 1 drug in this class
Grupo Argentino de Tratamiento de la Leucemia Aguda · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Sumitomo Pharma (Suzhou) Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Timolol + LCP — Competitive Intelligence Brief. https://druglandscape.com/ci/timolol-lcp. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab